Breast Cancer Research and Treatment

, Volume 125, Issue 3, pp 849–853 | Cite as

Association of a vascular endothelial growth factor gene 936 C/T polymorphism with breast cancer risk: a meta-analysis

  • Dae Sik Yang
  • Kyong Hwa Park
  • Ok Hee Woo
  • Sang Uk Woo
  • Ae-Ree Kim
  • Eun Sook Lee
  • Jae-Bok Lee
  • Yeul Hong Kim
  • Jun Suk Kim
  • Jae Hong Seo


Published studies on the association between the vascular endothelial growth factor (VEGF) gene 936 C/T polymorphism and breast cancer risk are inconclusive, and a meta-analysis is required to verify the association. Nine studies, including a total of 4,973 cases and 5,035 controls, were subjected to meta-analysis. When all eligible subjects were pooled for meta-analysis, the CT + TT genotypes were not associated with a significant decrease in breast cancer risk (odds ratio = 0.87; 95% confidence interval 0.75–1.02; P = 0.087). We also categorized by ethnicity (Caucasian, Asian, or mixed) for subgroup analysis, however, according to this subgroup analysis, we found no significant association between the CT and TT versus CC genotype with breast cancer risk reduction in any of the subgroups. We conclude that the VEGF gene 936 C/T polymorphism does not affect breast cancer risk.


VEGF 936 C/T polymorphism Breast cancer risk Meta-analysis 



This study was supported by a grant of the Korean Health 21 R&D Project, Ministry of Health and Welfare, Republic of Korea (0412-CR01-0704-001).

Conflict of interest



  1. 1.
    Bray F, McCarron P, Parkin DM (2004) The changing global patterns of female breast cancer incidence and mortality. Breast Cancer Res 6:229–239CrossRefPubMedGoogle Scholar
  2. 2.
    Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285:1182–1186CrossRefPubMedGoogle Scholar
  3. 3.
    Folkman J, Cole P, Zimmerman S (1966) Tumor behavior in isolated perfused organs: in vitro growth and metastases of biopsy material in rabbit thyroid and canine intestinal segment. Ann Surg 164:491–502CrossRefPubMedGoogle Scholar
  4. 4.
    Folkman J, Kalluri R (2004) Cancer without disease. Nature 427:787CrossRefPubMedGoogle Scholar
  5. 5.
    Semenza GL (1998) Hypoxia-inducible factor 1: master regulator of O2 homeostasis. Curr Opin Genet Dev 8:588–594CrossRefPubMedGoogle Scholar
  6. 6.
    Tacchini L, Bianchi L, Bernelli-Zazzera A, Cairo G (1999) Transferrin receptor induction by hypoxia. HIF-1-mediated transcriptional activation and cell-specific post-transcriptional regulation. J Biol Chem 274:24142–24146CrossRefPubMedGoogle Scholar
  7. 7.
    Wang GL, Semenza GL (1995) Purification and characterization of hypoxia-inducible factor 1. J Biol Chem 270:1230–1237CrossRefPubMedGoogle Scholar
  8. 8.
    Clauss M, Gerlach M, Gerlach H, Brett J, Wang F, Familletti PC, Pan YC, Olander JV, Connolly DT, Stern D (1990) Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J Exp Med 172:1535–1545CrossRefPubMedGoogle Scholar
  9. 9.
    Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF (1983) Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219:983–985CrossRefPubMedGoogle Scholar
  10. 10.
    Keck PJ, Hauser SD, Krivi G, Sanzo K, Warren T, Feder J, Connolly DT (1989) Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 246:1309–1312CrossRefPubMedGoogle Scholar
  11. 11.
    Maglione D, Guerriero V, Viglietto G, Delli-Bovi P, Persico MG (1991) Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. Proc Natl Acad Sci USA 88:9267–9271CrossRefPubMedGoogle Scholar
  12. 12.
    Tischer E, Mitchell R, Hartman T, Silva M, Gospodarowicz D, Fiddes JC, Abraham JA (1991) The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem 266:11947–11954PubMedGoogle Scholar
  13. 13.
    Vincenti V, Cassano C, Rocchi M, Persico G (1996) Assignment of the vascular endothelial growth factor gene to human chromosome 6p21.3. Circulation 93:1493–1495PubMedGoogle Scholar
  14. 14.
    Watson CJ, Webb NJ, Bottomley MJ, Brenchley PE (2000) Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. Cytokine 12:1232–1235CrossRefPubMedGoogle Scholar
  15. 15.
    Renner W, Kotschan S, Hoffmann C, Obermayer-Pietsch B, Pilger E (2000) A common 936 C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels. J Vasc Res 37:443–448CrossRefPubMedGoogle Scholar
  16. 16.
    Krippl P, Langsenlehner U, Renner W, Yazdani-Biuki B, Wolf G, Wascher TC, Paulweber B, Haas J, Samonigg H (2003) A common 936 C/T gene polymorphism of vascular endothelial growth factor is associated with decreased breast cancer risk. Int J Cancer 106:468–471CrossRefPubMedGoogle Scholar
  17. 17.
    Balasubramanian SP, Cox A, Cross SS, Higham SE, Brown NJ, Reed MW (2007) Influence of VEGF-A gene variation and protein levels in breast cancer susceptibility and severity. Int J Cancer 121:1009–1016CrossRefPubMedGoogle Scholar
  18. 18.
    Jacobs EJ, Feigelson HS, Bain EB, Brady KA, Rodriguez C, Stevens VL, Patel AV, Thun MJ, Calle EE (2006) Polymorphisms in the vascular endothelial growth factor gene and breast cancer in the Cancer Prevention Study II cohort. Breast Cancer Res 8:R22CrossRefPubMedGoogle Scholar
  19. 19.
    Jakubowska A, Gronwald J, Menkiszak J, Gorski B, Huzarski T, Byrski T, Edler L, Lubinski J, Scott RJ, Hamann U (2008) The VEGF_936_C>T 3′UTR polymorphism reduces BRCA1-associated breast cancer risk in Polish women. Cancer Lett 262:71–76CrossRefGoogle Scholar
  20. 20.
    Jin Q, Hemminki K, Enquist K, Lenner P, Grzybowska E, Klaes R, Henriksson R, Chen B, Pamula J, Pekala W, Zientek H, Rogozinska-Szczepka J, Utracka-Hutka B, Hallmans G, Forsti A (2005) Vascular endothelial growth factor polymorphisms in relation to breast cancer development and prognosis. Clin Cancer Res 11:3647–3653CrossRefPubMedGoogle Scholar
  21. 21.
    Kataoka N, Cai Q, Wen W, Shu XO, Jin F, Gao YT, Zheng W (2006) Population-based case–control study of VEGF gene polymorphisms and breast cancer risk among Chinese women. Cancer Epidemiol Biomarkers Prev 15:1148–1152CrossRefPubMedGoogle Scholar
  22. 22.
    Lin GT, Tseng HF, Yang CH, Hou MF, Chuang LY, Tai HT, Tai MH, Cheng YH, Wen CH, Liu CS, Huang CJ, Wang CL, Chang HW (2009) Combinational polymorphisms of seven CXCL12-related genes are protective against breast cancer in Taiwan. OMICS 13(2):165–172CrossRefPubMedGoogle Scholar
  23. 23.
    DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188CrossRefPubMedGoogle Scholar
  24. 24.
    Hu YF, Luscher B, Admon A, Mermod N, Tjian R (1990) Transcription factor AP-4 contains multiple dimerization domains that regulate dimer specificity. Genes Dev 4:1741–1752CrossRefPubMedGoogle Scholar
  25. 25.
    Mermod N, Williams TJ, Tjian R (1988) Enhancer binding factors AP-4 and AP-1 act in concert to activate SV40 late transcription in vitro. Nature 332:557–561CrossRefPubMedGoogle Scholar
  26. 26.
    Demicheli R (2001) Tumour dormancy: findings and hypotheses from clinical research on breast cancer. Semin Cancer Biol 11:297–306CrossRefPubMedGoogle Scholar
  27. 27.
    Uhr JW, Scheuermann RH, Street NE, Vitetta ES (1997) Cancer dormancy: opportunities for new therapeutic approaches. Nat Med 3:505–509CrossRefPubMedGoogle Scholar
  28. 28.
    Carmeliet P, Jain RK (2000) Angiogenesis in cancer and other diseases. Nature 407:249–257CrossRefPubMedGoogle Scholar
  29. 29.
    Smith KC, Bateman AC, Fussell HM, Howell WM (2004) Cytokine gene polymorphisms and breast cancer susceptibility and prognosis. Eur J Immunogenet 31:167–173CrossRefPubMedGoogle Scholar
  30. 30.
    Schneider BP, Radovich M, Sledge GW, Robarge JD, Li L, Storniolo AM, Lemler S, Nguyen AT, Hancock BA, Stout M, Skaar T, Flockhart DA (2008) Association of polymorphisms of angiogenesis genes with breast cancer. Breast Cancer Res Treat 111:157–163CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2010

Authors and Affiliations

  • Dae Sik Yang
    • 1
  • Kyong Hwa Park
    • 2
  • Ok Hee Woo
    • 3
  • Sang Uk Woo
    • 4
  • Ae-Ree Kim
    • 5
  • Eun Sook Lee
    • 4
  • Jae-Bok Lee
    • 4
  • Yeul Hong Kim
    • 2
  • Jun Suk Kim
    • 2
  • Jae Hong Seo
    • 2
  1. 1.Department of Radiation OncologyKorea University Guro HospitalSeoulKorea
  2. 2.Division of Medical Oncology, Department of Internal MedicineKorea University Guro HospitalSeoulKorea
  3. 3.Department of Diagnostic RadiologyKorea University Guro HospitalSeoulKorea
  4. 4.Department of SurgeryKorea University Guro HospitalSeoulKorea
  5. 5.Department of PathologyKorea University Guro HospitalSeoulKorea

Personalised recommendations